AbbVie executive: Cure rates will make hepatitis C drugs 'highly competitive'
This article was originally published in Scrip
Executive Summary
AbbVie’s hepatitis C drugs will compete well with new therapies developed by Gilead Sciences and other big rivals because the treatments will boast high cure rates, a company executive told Scrip.